Abstract:This study explores the role of Protein L‐isoaspartate (D‐aspartate) O‐methyltransferase (PCMT1) in conferring methotrexate (MTX) resistance in breast cancer cells. Through a series of experiments involving human breast cancer cell lines, the research demonstrates that PCMT1 is upregulated in MTX‐resistant cells. By employing siRNA techniques to silence the PCMT1 gene, the study observed a significant reduction in cell proliferation, migration, and invasion, alongside a decreased activation of the PI3K/Akt/STMN1 pathway, known for its role in cancer cell survival. Overall, the inhibition of PCMT1 enhanced the sensitivity of breast cancer cells to MTX, suggesting that PCMT1 might be a viable therapeutic target to overcome resistance. This study aimed to investigate whether silencing Protein L‐isoaspartate (D‐aspartate) O‐methyltransferase (PCMT1) expression can enhance the sensitivity of breast cancer cells to paclitaxel and its possible mechanism. Tumor tissues and adjacent histologically normal tissues were collected from patients with breast cancer admitted to our hospital. Human normal breast epithelial cells MCF10A, human breast cancer cells MCF‐7, and paclitaxel‐resistant breast cancer cells MCF‐7/PR were purchased. MCF‐7/PR cells were further grouped into negative control (NC) group, si‐PCMT1 group (transfected with si‐PCMT1), 740Y‐P group (treated with 740Y‐P, an activator of phosphatidylinositol 3‐kinase (PI3K)/ v‐Akt Murine Thymoma Viral Oncogene (AKT) signaling pathway), and si‐PCMT1 + 740Y‐P group (transfected with si‐PCMT1 and then treated with 740Y‐P). The expression level of PCMT1 in tissues and cells was detected by quantitative real‐time polymerase chain reaction (qRT‐PCR). Western blot analysis was used to detect the protein expression level of PCMT1 in tissues and cells as well as the protein level of p‐PI3K, PI3K, p‐Akt, Akt, and Stathmin1 (STMN1) in cells. 3‐(4,5)‐dimethylthiahiazo(‐z‐y1)‐3,5‐di‐phenytetrazoliumromide (MTT) and colony formation assays were used to determine cell viability, scratch assay was used to assess the migration ability of cells, and Transwell assay was used to assess the invasion ability of cells. The expression of PCMT1 was remarkably up‐regulated in breast cancer tissues and MCF‐7/PR cells. Silencing PCMT1 expression significantly inhibited the proliferation, migration, and invasion of MCF‐7/PR cells, and alleviated the resistance of cancer cells to paclitaxel. Additionally, silencing PCMT1 expression also inhibited the activation of PI3K/Akt/STMN1 pathway in MCF‐7/PR cells, while activating PI3K/Akt/STMN1 pathway significantly reversed the effect of silencing PCMT1 expression on MCF‐7/PR cells. PCMT1 is highly expressed in breast cancer tissues and MCF‐7/PR cells, and silencing PCMT1 expression can not only inhibit the development of breast cancer but also enhance paclitaxel sensitivity. Its mechanism of action may be achieved by inhibiting PI3K/Akt/STMN1 signaling.

Inhibition of Isoprenylcysteine Carboxylmethyltransferase Sensitizes Common Chemotherapies in Cervical Cancer Via Ras-dependent Pathway.

Inhibition of N-Linked Glycosylation by Tunicamycin Enhances Sensitivity to Cisplatin in Human Head-And-Neck Carcinoma Cells

Icotinib Hydrochloride Enhances Chemo- And Radiosensitivity By Inhibiting Egfr Signaling And Attenuating Rad51 Expression And Function In Hela S3 Cells

C-Myc-induced Chemosensitization is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-Kappa B Activity in Pancreatic Cancer Cells.

ICMT Contributes to Hepatocellular Carcinoma Growth, Survival, Migration and Chemoresistance Via Multiple Oncogenic Pathways.

Isoprenylcysteine carboxylmethyltransferase is associated with nasopharyngeal carcinoma chemoresistance and Ras activation.

BET Protein Inhibition Evidently Enhances Sensitivity to PI3K/mTOR Dual Inhibition in Intrahepatic Cholangiocarcinoma

Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma

MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

Isoprenylcysteine Carboxyl Methyltransferase is Critical for Glioblastoma Growth and Survival by Activating Ras/Raf/Mek/Erk

Tumor Microenvironment Responsive Pmpc-Based Nanocapsule for Enhanced Cancer Chemotherapy

Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.

Mitomycin C and its analog trigger cytotoxicity in MCF-7 and K562 cancer cells through the regulation of RAS and MAPK/ERK pathways

Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer

Isoprenylcysteine carboxyl methyltransferase promotes the progression of tongue squamous cell carcinoma via the K-Ras and RhoA signaling pathways

Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer

Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway

A Novel CREB5/TOP1MT Axis Confers Cisplatin Resistance Through Inhibiting Mitochondrial Apoptosis in Head and Neck Squamous Cell Carcinoma.

Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.

Inhibition of PI3K/mTOR Increased the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin Via Interference with Mitochondrial-Lysosomal Crosstalk.

Isoprenylcysteine carboxyl methyltransferase (ICMT) promotes invadopodia formation and metastasis in cancer cells